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Abstract
Background: Extracellular matrix protein 1 (ECM1) and vascular endothelial growth factor-C (VEGF-C) are secretory
glycoproteins that are associated with lymphangiogenesis; these proteins could, therefore, play important roles in
the lymphatic dissemination of tumors. However, very little is known about their potential roles in
lymphangiogenesis. The aim of this study was to investigate whether correlations exist between ECM1 and VEGF-C
in human breast cancer, lymphangiogenesis, and the clinicopathological characteristics of the disease.
Methods: ECM1 and VEGF-C mRNA and protein expression levels in 41 patients were investigated using real-time
reverse transcriptase polymerase chain reaction (RT-PCR), or immunohistochemical (IHC) staining of breast cancer
tissue, matched noncancerous breast epithelial tissues, and suspicious metastatic axillary lymph nodes. D2-40
labelled lymph vessels and lymphatic microvessel density (LMVD) were counted. Correlations between ECM1 or
VEGF-C protein expression levels, LMVD, and clinicopathological parameters were statistically tested.
Results: The rate of ECM1 positive staining in breast cancer tissues was higher (31/41, 75.6%) than that in the
corresponding epithelial tissues (4/41, 9.8%, P < 0.001) and lymph nodes (13/41, 31.7%, P < 0.001). Similarly, the VEGF-C
expression rate in cancer specimens was higher (33/41, 80.5%) than in epithelial tissues (19/41, 46.3%, P < 0.01) or
lymph nodes (15/41, 36.6%, P < 0.01). Higher ECM1 and VEGF-C mRNA expression levels were also detected in the
tumor tissues, compared to the non-cancerous tissue types or lymph nodes (P < 0.05). ECM1 protein expression was
positively correlated with the estrogen receptor status (P <0 . 0 5 )a n dL M V D( P < 0.05). LMVD in the ECM1- and VEGF-C-
positive tumor specimens was higher than that in the tissue types with negative staining (P < 0.05).
Conclusions: Both ECM1 and VEGF-C were overexpressed in breast cancer tissue samples. ECM1 expression was
positively correlated with estrogen responsiveness and the metastatic properties of breast cancer. We conclude,
therefore, that ECM1 and VEGF-C may have a synergistic effect on lymphangiogenesis to facilitate lymphatic
metastasis of breast cancer.
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Breast cancer is one of the most common cancers and
the leading cause of death attributed to cancer among
women in economically developed countries [1]. Unlike
the hematologic system, the lymphatic system is the pri-
mary pathway to metastatic disease [2]. Recent studies
have demonstrated that there is expansion of lymphatic
networks within lymph nodes prior to the onset of
metastasis [3]. Thus, the status of lymph node metastasis
can be predicted by the presence of early lymphatic inva-
sion. Lymphatic microvessel density (LMVD) reflects the
status of lymphangiogenesis and lymphatic vessel remo-
deling. Increased numbers of lymphatic microvessels pro-
vide more opportunities for tumor cells to disseminate to
the lymphatic system; hence, LMVD has been shown to
be correlated with lymphangiogenic factors, the presence
of lymphatic metastasis and a poor prognosis in breast
cancer [4].
Extracellular matrix protein 1 (ECM1) was originally
derived from the osteogenic mouse stromal cell line MN7
[5]. The 85-kDa glycoprotein has a close association with
vascularity. It has recently been suggested that a homozy-
gous frameshift mutation in ECM1 led to a failure of
human mucocutaneous lymphangiogenesis [6], thus indi-
cating a possible role for ECM1 in lymphangiogenesis.
ECM1 is overexpressed in various malignant epithelial
tumors [7-10], and has been identified as a marker of poor
clinical prognosis [7-9]. However, very little is known
about possible correlations between ECM1 and malignant
lymphangiogenesis or lymphatic metastasis.
Lymphangiogenesis is also correlated with vascular
endothelial growth factor-C (VEGF-C) expression, as
demonstrated by numerous investigations [11,12]. VEGF-
C initiates activation and phosphorylation of VEGFR-3
(Flt-4) which leads to PI3K-dependent Akt activation and
PKC-dependent activation of the p42/p44 MAPK pathway.
This process can protect lymphatic endothelial cells from
apoptosis and stimulate their proliferation and migration
in vitro [13,14]. In addition, genetically engineered mice
conditionally overexpressing VEGF-C showed hyperplasia
of lymphatic vessels, whereas VEGF-C-null mouse
embryos completely lacked lymphatic vasculature [15].
Data from two preclinical studies provide direct evidence
that an increased level of VEGF-C can promote intratu-
moral and peritumoral lymphangiogenesis, as well as
lymphatic tumor spread to regional nodes [16,17].
The present study was designed to investigate the
expression pattern of ECM1 and VEGF-C in tumor spe-
cimens, their peritumoral normal counterparts and axil-
lary lymph nodes from 41 breast cancer patients. We
also evaluated whether ECM1 and VEGF-C expression
correlated with lymphatic microvessel density or the
clinicopathological characteristics of the disease.
Methods
Patients and specimens
Fresh surgical specimens from 41 randomly selected
female patients who had undergone surgery in the breast
surgery department at the First Affiliated Hospital of Xia-
men University (February 2009 to February 2010) were
used. The average age at time of diagnosis was 53 years
(range: 29-76 years). None of the patients had received
preoperative treatment, such as radiotherapy or che-
motherapy. Metastatic tumors from other tissue origins
were excluded from the study. All cases had three samples
collected as follows: breast cancer tissue, the correspond-
ing noncancerous breast epithelial tissue (located more
than 5 cm away from the tumor margins), and one of the
suspicious metastatic lymph nodes from the same side of
the armpit as judged by the naked eye. The specimens
were divided into two parts: one part was quickly frozen in
liquid nitrogen for RNA extraction, the other fixed for
immunostaining and routine histological characterization.
Institutional Ethics Committee approval for the project
was provided prior to commencement of the study and was
in compliance with the Helsinki Declaration. Approval to
conduct this study was obtained from the Human Subjects
Office of the Institutional Research Board at the Xiamen
University. Written informed consent was obtained from
patients or their relatives. Cases were evaluated for histolo-
gical type, tumor grade and histological grade (according to
the Nottingham histological score) [18]. The status of
lymph node metastasis, estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor
receptor 2 (HER2/neu) score were evaluated according to
the American Joint Committee on Cancer (AJCC, seventh).
Real-time RT-PCR
Total RNA was extracted using Trizol reagent according
to the manufacturer’s protocol (Invitrogen, USA). Reverse
transcription of total RNA into cDNA was conducted
using TaKaRa Reverse Transcription Reagents (Takara Bio
Inc., Japan) at 37°C for 15 min, followed by 85°C for 5 s.
Primers were designed using Primer Premier 5.0 software
(Premier, Canada) and synthesized by Invitrogen. ECM1
mRNA sequence-specific primers [GenBank Accession
No. NM 004425.3] with the following sequences were
used: Forward (F): 5’-CAAATCTGCCTTCCTAACCG-3’;
Reverse (R): 5’-AAGCAGGAGAACCGAGCC-3’. VEGF-C
mRNA [GenBank Accession No. NM 005429.2] primers
were as follows: F: 5’-GGGAAGGAGTTTGGAGT-3’;R :
5’-GCATCGGCAGGAAGT-3’. The house-keeping gene
GAPDH mRNA was used as a reference because it is
expressed at a constant level in cells. The GAPDH mRNA
primers used were as follows: F: 5’-GAAGGTGAAGG
TCGGAGTC-3’;R :5 ’-GAAGATGGTGATGGGATTTC-
3’. Real-time quantitative PCR was performed using the
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® Premix Ex Taq™ II PCR kit (Takara Bio
Inc., Japan) in a Roche Lightcycler 480 instrument (Roche,
Switzerland). Reactions were performed in 10 μl volumes
with denaturation at 95°C for 5 s, annealing at 58°C for 15
s, and extension at 72°C for 20 s, over 40 cycles. The sys-
tem automatically monitors binding of a fluorescent dye
to double-strand DNA by real-time detection of the fluor-
escence emitted during each cycle of PCR amplification.
Melting curves were analysed to ensure only single ampli-
cons of the expected size were quantified. To determine
the fold change in expression and to normalize ECM1 and
VEGF-C expression levels, triplicates of the cycle threshold
(Ct) for the target gene were averaged and divided by the
average of the triplicate obtained from GAPDH in the
same specimen.
IHC staining and evaluation
4-μm sections of formalin-fixed, paraffin-embedded tis-
sues were deparaffinized, stepwise rehydrated and the
endogenous peroxide blocked. For both ECM1 and D2-
40 staining, slides were processed with antigen retrieval
which was achieved by boiling the slides in citrate buffer
(pH 6.0) for 1.5 min. For VEGF-C staining, slides were
boiled in an EDTA solution for 20 min before cooling.
Nonspecific binding was blocked using 10% non-immune
goat serum (Santa Cruz, USA.) for 10 min. Sections were
incubated for 120 min at room temperature with anti-
ECM1 antibody (Abcam, UK, clone SC-05) at a 1: 50
dilution, or with anti-VEGF-C antibody (Abcam, UK) at
a 1: 200 dilution, or with D2-40 antibody (Abcam, UK,
clone D2-40) at a 1:40 dilution. After rinsing, sections
were incubated with the EnVision™ Detection System
(Dako, Denmark), counterstained with haematoxylin,
dehydrated, and mounted. Negative controls were pro-
cessed using the same procedure, except that 10% non-
immune mouse serum (Santa Cruz) was used in place of
the primary antibody. No detectable staining was
observed in any of the negative control slides.
LMVD was assessed by counting the number of D2-40
immunostained vessels on tissue sections. Morphometric
analyses were estimated independently by two observers
that had no prior knowledge of the patients’ clinico-
pathologic data. As previous reported [19], we first iden-
tified the area containing the most stained vessels ("hot
spots”) by scanning the sections at low magnification
(40×); then counted the number of positive vessels in
two high magnification fields (200×). We defined those
vessels as lymphatics if they were lined by a single layer
of immunopositive flattened endothelial cells with a vas-
cular lumen, in the presence or absence of lymphocytes
and absence of erythrocytes [20]. LMVD in tumor sec-
tions was determined by averaging the number of total
lymphatic vessels in all the fields of each slide, including
within the tumor or at the periphery of the tumor. The
mean visual microvessel density was calculated as the
average of four counts (two of the authors: two micro-
scopic fields). Discordant cases were recounted, and the
consensus resolved any discrepancy of more than 10%
of the microvessel count.
ECM1 IHC staining results were expressed in two
ways [10]: (1) the percentage of cells staining on a
graduated percentage (0-100%); 10-30% of tumor cells
in the section were positive (+); 30-60% of tumor cells
were positive (++); 60-100% of tumor cells were posi-
tive (+++). For analysis as a dichotomous variable,
staining < 10% was classified as ECM1-negative and ≥
10% classified as ECM1-positive; this allowed compari-
sons to be made against previous studies. (2) The per-
centage of positive staining = (the numbers of positive
samples/the numbers of samples tested) × 100%. The
semi-quantitative assessment of VEGF-C staining was
conducted as described for the ECM1 staining
assessment.
Statistics
Data were analyzed using SPSS (version 17.0; Chicago, IL,
USA). The distribution of quantitative variables was tested
for normality using the Kolmogorov-Smirnov test. Data
which were normally distributed were applied to para-
metric statistical analysis and results expressed as the
mean ± the standard error of the mean (S.E.M.). Unpaired
Student’s t-test was used to compare two sets of data and
a one-way analysis of variance (ANOVA) with Dunnett’s
post-test was used for comparisons of more than two data
sets. Non-parametric statistics were applied to data that
was not normally distributed. c
2 tests, Yates’ correction, or
Fisher’s exact test were used for qualitative independent
variables. The Bonfferoni correction of the a-value for
multiple comparisons was conducted. Correlations
between two variables were assessed using Spearman’sr h o
test. All statistical tests were two-sided. A P-value of less
than 0.05 was considered significant.
Results
LMVD assessment
D2-40 is a commercially available mouse monoclonal
antibody directed against human podoplanin, which is a
mucin-type transmembrane protein present in lymphatic
endothelial cells [21]. It is a specific marker for lympha-
tic endothelium and has proven valuable in distinguish-
ing lymph vessels from blood vessels and detecting
lymphatic invasion in various malignant neoplasms
[22-24]. It has been reported that the basal epithelial
cell layers of the epidermis and the myoepithelial cells
of human breast tissue, prostate and salivary gland tis-
sue can also be stained by D2-40; but the morphology
of these cells are distinct from the characteristic mor-
phology of lymphatic endothelium [25,26].
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located in the cytoplasm or cell membrane of the lym-
phatic endothelial cells, whilst the tumor cells and blood
vessel endothelium had no D2-40 staining. The ductal
cancer in situ (DCIS) foci displayed weak residual dis-
continuous myoepithelial staining. We found that the
tumor lymphatic vessel invasion (LVI) was established
when at least one tumor cell cluster (“tumor emboli”)
was clearly visible inside a D2-40 positive lymph vessel,
according to criteria established by Hasebe et al. [27].
Representative examples of the staining obtained in
these studies are shown in Figure 1.
For LMVD assessment, we found that the mean num-
ber of visual microvessels was 12.95 ± 1.73 (range 1.04-
42.10) lymphatic microvessels per 200× field (LMV per
200× field) in the 41 breast cancer specimens. Within
the same subjects, the mean LMVD in normal breast
tissue and lymph nodes were 2.24 ± 0.18 (range 1.00-
5.03) and 5.49 ± 0.52 (range 0-32.01) LMV per 200×
field, respectively. The differences observed in the
LMVD between the three tissue types were statistically
significant (Friedman test, P < 0.01). Dunnett’s post-test
showed that the mean LMVD in tumor tissues was
higher than that observed in the normal breast tissues
(P < 0.01) and lymph nodes (P < 0.01). However,
LMVD differences between the normal tissue and the
lymph nodes were not statistically significant (P > 0.05).
The mean LMVD in the lymph nodes of the metastasis
group was higher than that in the non-metastasis group
(Mann-Whitney test, P = 0.003). Differences in the
LMVD in the metastasis and non-metastasis groups was
not found to be statistically significant in the cancer tis-
sues, nor the normal breast epithelium (P = 0.409 and
P = 0.377, respectively) (Table 1).
Our data show that LMVD in the breast cancer tissue
was significantly higher than that in the normal tissues.
We also found that LMVD in the lymph nodes with
metastasis was higher than that without metastasis. Lym-
phatic vessels have discontinuous basement membranes
and lack tight interendothelial junctions. Hence, it is possi-
ble that lymphatic vessels might be easier for tumor cells
to enter than blood vessels [2], and that LMVD enhance-
ment could significantly increase the potential for tumor
cells to invade the surface of lymphatic vessels [28].
Figure 1 D2-40 labelled LMVD with IHC staining (200×). A-C Invasive ductal breast cancer: A. Stained lymphatic microvessels within a
peripheral tumor (long arrow) with dilated tubes. Capillary vessel (short arrow) and tumor cell clusters were not stained; B. The central-tumor
vascular structures appear linear, small and flattened, cluttered and densely arrayed; C. a cluster of tumor cells (arrow) in a stained vessel, or
“tumor emboli”. D. Luminal epithelial cells with D2-40 negative staining. Myoepithelial cells from normal ducts and lobules had positive D2-40
immunostaining (short arrow), but with a granular, branching membranous staining pattern that is distinct from the characteristic staining
pattern of lymphatic endothelium (long arrow). E-F Metastatic lymph nodes: E. stained lymphatic microvessels in the metastasis, with irregular
lumens and cracked tube walls; F. dilated lymphatic microvessel sub-capsular metastasis with no staining of tumor cells within it; defined as
lymphatic vessel invasion (LVI) (arrow).
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We used real-time RT-PCR to determine the mean rela-
tive expression levels of ECM1 mRNA (Table 2) and
VEGF-C mRNA (Table 3) in breast cancer specimens, nor-
mal epithelia and lymph nodes from the patients. Differ-
ences in the ECM1 mRNA expression levels among these
tissues were statistically significant (one-way ANOVA, P <
0.01) (Table 2). Multiple comparison analysis (Tukey’s
test) showed that ECM1 mRNA expression levels in the
breast cancer samples were significantly higher overall,
compared to the normal tissue (P < 0.05) or to the lymph
nodes (P < 0.05); however, no differences were found
between normal tissues and lymph nodes (P >0 . 0 5 ) .I n
general, the results of VEGF-C mRNA expression among
the three tissue types showed the same trends as those
obtained for ECM1 (Table 3).
We found that ECM1 was mainly located in the cyto-
plasm of the cells, with scant staining noted on the cell
membrane or the stroma; no nuclear staining was seen.
Within the draining lymph nodes, ECM1 staining was spe-
cific for the metastatic cancer cells and occurred primarily
in their cytoplasm. Notably, in the normal breast epithe-
lium, there was little or no staining at all. Representative
examples of the ECM1 staining patterns are shown in
Figure 2. The ECM1 positive staining rates among tumor
tissue (31, 75.6%), normal breast tissue (4, 9.8%) and
lymph nodes (13, 31.7%) were significantly different (c
2 =
39.08, P < 0.01). Multiple comparison (c
2 division, a =
0.0125) analysis showed the ECM1 positive staining rate in
cancer tissue was higher than in normal tissue and the
lymph nodes (P < 0.001). Differences in the ECM1 positive
staining rate between normal tissues and lymph nodes
were not significant, however (P > 0.0125, Table 2).
In breast cancer cells, VEGF-C staining was observed in
the cytoplasm; such staining was often more intense at
the invasive edge or in the intraductal component (Figure
3). In contrast, very little or no staining was observed in
normal ductal epithelium. According to the criteria used
to evaluate the immunostaining, VEGF-C expression in
the cancer specimens (33/41, 80.5%) was higher than that
in the normal tissues and lymph nodes (19/41, 46.3% and
15/41, 36.6%, respectively; P < 0.01). However, the differ-
ence in the values obtained from the normal epithelium
and the matched lymph nodes was not significant (P >
0.0125, Table 3).
Differences in ECM1 and VEGF-C expression between the
metastatic and non-metastatic groups
Statistically significant differences in ECM1 mRNA
expression in tumor tissues between the metastasis group
and the non-metastasis group were not found (Mann-
Whitney test, P = 0.314); no statistically significant differ-
ences were found for the normal breast epithelium tis-
sues or the lymph nodes, between the metastasis and
non- metastasis groups (P = 0.754 and P = 0.178, respec-
tively; Table 4). The results of VEGF-C mRNA expression
between the metastasis group and the non-metastasis
group showed similar trends as those observed for ECM1
(Table 5).
Differences in the ECM1 positive staining rates
between metastatic (15/19, 78.9%) and non-metastatic
(16/22, 72.7%) tumors were not significant (P > 0.05).
Similar results were obtained for the normal tissue
groups (metastatic: 3/19, 15.8%; non-metastatic:1/22,
4.55%) (Fisher’se x a c tt e s t ,P > 0.05, Table 4). The ECM1
positive rate in the lymph node metastases was 68.4%
(13/19). Likewise, no differences were apparent in VEGF-
C expression in the three tissues (i.e., cancer tissue, nor-
mal tissue and lymph nodes) between the metastasis and
non-metastasis groups (Fisher’s exact test, P >0 . 0 5 ,
Table 5).
Table 1 Comparison of LMVD between the metastasis
and non-metastasis groups
LMVD (LMV per 200× field of vision)
Tissue type Metastasis
group
Non-metastasis
group
U P
Cancer
tissues
15.16 ± 2.94 11.05 ± 1.97 177.0 0.409
Normal
tissues
2.42 ± 0.27 2.09 ± 0.24 176.0 0.377
Lymph nodes 9.32 ± 2.16 2.18 ± 0.32 97.5 0.003*
* P < 0.05 is considered statistically significant
Abbreviation: LMVD lymphatic microvessel density; LMV per 200× field of
vision: lymphatic microvessel 200× field of vision
Table 2 ECM1 expression in breast cancer specimens, normal epithelium and lymph nodes
ECM1mRNA expression Positive Staining grades of ECM1
Tissue type N F rate (%) - + ++ +++ c
2
Cancer tissues 41 1.25 ± 0.33
A 75.6
D 10 22 7 2
Normal tissues 41 0.46 ± 0.10
B 9.8
E 37 3 1 0
Lymph nodes 41 0.38 ± 0.18
C 4.86** 31.7
F 28 9 3 1 39.08**
** P < 0.01, P < 0.05 is considered statistically significant
“+”, “++” and “+++” for ECM1 immunochemistry staining was all grouped together as “+”
A vs. B and A vs. C: P < 0.05, respectively; B vs. C: P > 0.05
c
2 division:a = 0.05/4 = 0.0125; D vs. E and D vs. F: P < 0.001, respectively; E vs. F: P > 0.0125
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positive staining rate between the primary tumor (15/19,
78.9%) and the metastatic focus (13/19, 68.4%) was not
statistically significant (P >0 . 0 5 ,T a b l e4 ) .I nt w oo ft h e
cases, we found that the primary tumor was ECM1
negative, whilst ECM1 was expressed in the correspond-
ing lymph node metastases. Similarly, the difference in
the VEGF-C positive staining rate between the primary
tumor and the metastatic focus was not significant (P >
0.05, Table 5). In addition, the VEGF-C staining rates in
the two tissue types (i.e. cancer tissues and lymph
nodes) were both 68.4% (13/19), although the cases that
had positive staining did not all coincide with each
other.
ECM1 and VEGF-C expression profiles and clinical
characteristics
We evaluated whether correlations exist between
expression of ECM1 or VEGF-C and the clinicopatholo-
gical characteristics of the disease, (i.e. age; histological
type or grade; tumor size; lymph node, ER, and PR
status and Her-2/neu score). Tables 6 and 7, summarize
the ECM1 and VEGF-C data, respectively. ECM1 mRNA
expression was not associated with any of the clinico-
pathological characteristics tested (Unpaired t test with
Welch’s correction, P > 0.05). The ECM1 protein posi-
tive rate was found to be associated with the status of
the ER (c
2, P = 0.045). The ER status of patients with
E C M 1 - p o s i t i v et u m o r sw e r em o r el i k e l yt ob ep o s i t i v e
than those without ECM1 staining. However, ECM1
staining was not correlated with tumor size, lymph node
status, PR status or the Her-2/neu score (Fisher’se x a c t
test, P >0 . 0 5 ) .W ef o u n dt h a tVEGF-C mRNA and pro-
tein expression were not associated with any of the clin-
icopathological characteristics tested (P >0 . 0 5 ,
respectively; Table 7).
Correlations between LMVD and ECM1 or VEGF-C
We found that histological sections that were ECM1-
positive had higher LMVDs (Figure 4). As shown in
Table 8, differences in LMVD between the ECM1-posi-
tive cases and ECM1-negative cases were statistically
Table 3 VEGF-C expression in breast cancer specimens, normal epithelium and lymph nodes
VEGF-C mRNA expression Positive Staining grades of VEGF-C
Tissue type N F rate (%) - + ++ +++ c
2
Cancer tissues 41 2.63 ± 0.32
A 80.5
D 82 09 4
Normal tissues 41 1.08 ± 0.17
B 46.3
E 22 17 2 0
Lymph nodes 41 1.33 ± 0.17
C 15.05*** 36.6
F 26 10 3 2 23.08***
*** P < 0.001, P < 0.05 is considered statistically significant
“+”, “++” and “+++” for VEGF-C immunochemistry staining was all grouped together as “+”
A vs. B and A vs. C: P < 0.01, respectively; B vs. C: P > 0.05
c
2 division:a = 0.05/4 = 0.0125; D vs. E and D vs. F: P < 0.01, respectively; E vs. F: P > 0.0125
Figure 2 Representative IHC staining of ECM1. A-D: ECM1 was detected primarily in the cytoplasm of breast cancer cells (200×): A. ECM1
negative; B. + ECM1 staining; C. ++ ECM1 staining; D. +++ ECM1 staining. E-F normal breast epithelium (200×): E. ECM1 negative; F. breast
ductal epithelial cells with cytoplasmic ECM1 staining classified as +. G-H lymph node metastases: G. metastatic cells with ECM1 staining (200×)
classified as +; H. cytoplasm of metastatic cells with ECM1 staining (100×) classified as ++.
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test, P = 0.045), and the lymph nodes (Mann-Whitney
test, P < 0.001). A positive correlation was further estab-
lished between the LMVD and ECM1 staining intensity
in both the breast cancer sections, and the lymph node
sections (Spearman’s correlation coefficient 0.347 and
0.604, respectively; P < 0.05, Table 9). The correlation
was not linear, however.
We noted that the LMVD in the VEGF-C-positive
lymph nodes was higher than that in the VEGF-C-negative
ones (Mann-Whitney test, P < 0.001); LMVD in the lymph
nodes was correlated with VEGF-C staining (Spearman’s
correlation coefficient: 0.566, P < 0.001). However, LMVD
in the breast cancer specimens was not associated with
VEGF-C staining (P > 0.05, Table 10).
We further analysed the LMVD in breast cancer tissue
and lymph nodes for both ECM1 and VEGF-C staining
(Table 11). The LMVD in both ECM1- and VEGF-C-
positive (E+V+) tumor specimens was higher than that in
both the ECM1- and VEGF-C-negative (E-V-) ones
(Mann-Whitney test, P = 0.029; Figure 5A). Additionally,
the LMVD in both E+V- and E-V+ tumor specimens was
higher than in the E-V- specimens (Mann-Whitney test,
P > 0.05). We also found that LMVD in E+V+ tumor spe-
cimens was higher than in the E-V+ and E+V- ones,
although the differences did not reach statistical signifi-
cance (Mann-Whitney test, P >0 . 0 5 ) .H o w e v e r ,L M V D
in the lymph nodes of the different assemblies for both
ECM1 and VEGF-C staining (i.e. E-V-, E-V+, E+V- and E
+V+) showed a statistically significant difference (one
way ANOVA, P = 0.025), but did not show a significant
tendency (Figure 5B).
Discussion
The lymphangiogenic properties of ECM1 have been
reported elsewhere [6]. However, whether this protein is
involved in the formation of new lymphatic vessels in
tumor progression is not fully understood. The present
study highlighted a positive correlation between ECM1
protein expression and LMVD, in both the tumor speci-
mens and the lymph nodes. In addition, VEGF-C expres-
sion in the lymph nodes was correlated with LMVD.
These results indicate that ECM1 has a closer relation-
ship with LMVD than VEGF-C. LMVD reflects the status
of lymphangiogenesis and the incidence of lymphatic
metastasis. Therefore, like VEGF-C, ECM1 appears to be
Figure 3 Representative IHC staining of VEGF-C (200×). A-D: VEGF-C staining was mainly located in the cytoplasm of breast cancer cells: A.
VEGF-C negative; B. + VEGF-C staining; C. ++ VEGF-C staining; D. +++ VEGF-C staining. E-F normal breast epithelium: E. VEGF-C negative; F.
breast ductal epithelial cells classified ++ for cytoplasmic VEGF-C staining. G-H lymph node metastases: G. metastatic cells were negative for
VEGF-C staining; H. cytoplasm of metastatic cells classified + for VEGF-C staining.
Table 4 Comparison of ECM1 expression levels between the metastasis- and non-metastasis groups
ECM1 mRNA expression ECM1 positive rate (%)
Tissue type Metastasis Non-metastasis P Metastasis Non-metastasis P
Cancer tissues 1.11 ± 0.39 1.48 ± 0.54 0.314 78.9(15/19) 72.7(16/22) > 0.05
Normal tissues 0.53 ± 0.18 0.40 ± 0.09 0.754 15.8(3/19) 4.55(1/22) > 0.05
Lymph nodes 0.62 ± 0.36 0.20 ± 0.13 0.178 68.4(13/19) (0/22) < 0.01*
* P < 0.05 is considered statistically significant
Within parenthesis: number of eligible cases
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contribute to an increased rate of metastatic spread of
breast cancer cells to the lymph nodes. Furthermore, the
LMVD in both ECM1- and VEGF-C-positive tumor spe-
cimens was statistically higher than that noted in the
both of the ECM1- and VEGF-C-negative ones as well as
the ECM1- or VEGF-C-positive ones; this suggests that
ECM1 and VEGF-C might have a synergistic effect on
lymphangiogenesis in breast cancer.
In the present study, cytoplasmic ECM1 was signifi-
cantly elevated in breast cancer specimens, compared to
the peritumoral normal counterparts from the same
patients. Han et al. [29] and Wang et al. [10] also reported
that ECM1 was overexpressed in breast cancer tissues.
Moreover, the ECM1 mRNA and protein levels detected
by real-time RT-PCR and IHC were consistent with each
other, suggesting that the elevated ECM1 protein expres-
sion levels may derive from increased transcription of the
gene.
A previous study demonstrated that breast cancers
with lymph node metastasis were more likely to be
ECM1-positive (10/13, 76.9%) than those without metas-
tasis (3/9, 33.3%) [10]. However, we failed to identify any
statistically significant differences in ECM1-staining
from different patients with regard to lymph node
metastasis; this finding is in accordance with an analysis
Table 5 Comparison of VEGF-C expression levels between the metastasis- and non-metastasis groups
VEGF-C mRNA expression VEGF-C positive rate (%)
Tissue type Metastasis Non-metastasis P Metastasis Non-metastasis P
Cancer tissues 2.27 ± 0.39 2.92 ± 0.48 0.455 68.4 (13/19) 90.9 (20/22) > 0.05
Normal tissues 0.95 ± 0.18 1.18 ± 0.27 0.948 47.4 (9/19) 45.5 (10/22) > 0.05
Lymph nodes 1.21 ± 0.23 1.46 ± 0.24 0.314 68.4 (13/19) 9.1 (2/22) < 0.001*
* P < 0.05 is considered statistically significant
Within parenthesis: number of eligible cases
Table 6 Correlations between ECM1 expression and clinicopathological characteristics
Clinicopathological characteristics N ECM1 positive P ECM1 mRNA expression P
N rate (%)
Age (years)
< 60 30 22 73.3 1.54 ± 0.43
≥ 60 11 9 81.8 0.700 0.68 ± 0.46 0.183
Histological grade
(invasive ductal)
I+II 16 12 75.0 1.76 ± 0.71
III+IV 20 16 80.0 0.720 1.18 ± 0.39 0.483
Tumor size
T1 15 10 66.7 1.49 ± 0.60
T2 23 19 82.6 1.34 ± 0.46
T3 3 2 66.7 0.512 0.11 ± 0.08 0.275
Lymph nodal status
N0 22 16 72.7 1.48 ± 0.54
N1 12 10 83.3 1.32 ± 0.58
N2 5 3 60.0 0.81 ± 0.60
N3 2 2 100 0.121 0.54 ± 0.50 0.424
Estrogen receptor status
- 10 5 50.0 1.02 ± 0.62
+~+++ 31 26 83.9 0.045* 1.40 ± 0.41 0.611
Progesterone receptor status
- 8 4 50.0 1.32 ± 0.90
+~+++ 33 27 81.8 0.082 1.30 ± 0.37 0.987
HER2/neu score
- (0-1) 13 11 84.6 1.48 ± 0.69
+ (2-3) 28 20 71.4 0.458 1.23 ± 0.39 0.757
“+”, “++” and “+++” for ECM1 immunochemistry staining was all grouped together as “+”
* P < 0.05 is considered statistically significant
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Clinicopathological characteristics N VEGF-C positive P VEGF-C mRNA expression level P
N rate (%)
Age (years)
<60 30 23 76.7 2.41 ± 0.33
≥ 60 11 10 90.9 0.412 3.20 ± 0.76 0.505
Histological grade
(invasive ductal)
I+II 16 14 87.5 2.72 ± 0.58
III+IV 20 14 70.0 0.257 2.65 ± 0.45 0.908
Tumor size
T1 15 12 80.0 3.00 ± 0.63
T2 23 18 78.3 2.14 ± 0.31
T3 3 3 100 0.670 4.58 ± 1.68 0.237
Lymph nodal status
N0 22 20 90.9 2.92 ± 0.48
N1 12 8 66.7 2.10 ± 0.53
N2 5 3 60.0 2.51 ± 0.86
N3 2 2 100 0.606 2.65 ± 0.07 0.710
Estrogen receptor status
- 10 9 90.0 2.42 ± 0.63
+~+++ 31 24 77.4 0.653 2.69 ± 0.38 0.606
Progesterone receptor status
- 8 6 75.0 2.14 ± 0.75
+~+++ 33 27 81.8 0.642 2.75 ± 0.35 0.217
HER2/neu score
- (0-1) 13 10 76.9 2.70 ± 0.66
+ (2-3) 28 23 82.1 0.693 2.60 ± 0.36 0.918
“+”, “++” and “+++” for VEGF-C immunochemistry staining was all grouped together as “+”
Figure 4 Representative examples of D2-40 and ECM1 staining in the matched sections (100×). Sections with ECM1-positive staining had
higher lymphatic microvessel densities. A-D: Lymphatic microvessels labelled with D2-40. E-H: ECM1 IHC staining: Panels E and G: ECM1
negative; Panels F and H: ++ ECM1 staining. A-B, E-F: invasive ductal breast cancer; C-D, G-H: lymph nodes with metastasis. Panels A and E, B
and F, C and G, D and H represent matched sections obtained from the same specimen, respectively.
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ECM1 expression was not statistically associated with
the status of lymph node metastasis [8]. Differences
observed between our findings and those reported by
Wang et al. [10] and Lal et al. [8] could be related to a
number of differences between the studies; for example,
differences in the number of cases (i.e., sample size
effects), use of antibodies from different suppliers, or
the different compositions of the histological types. Par-
ticipants in the Lal et al. [8] study, as well as our own,
mainly presented with infiltrating breast cancer, but
Wang et al. [10] did not specify the breast cancer stage.
In our study, differences in the relative ECM1 mRNA
expression levels between the metastasis and non-metasta-
sis cases were not statistically significant. Additionally, we
found VEGF-C expression had no statistically significant
difference between the metastasis and non-metastasis
cases, which is consistent with that reported by Kinoshita
et al. [30]. However, other studies have reported associa-
tions between VEGF-C expression and lymph node metas-
tasis [31,32]. Methodological variability, particularly with
respect to the antibodies and specimens used, may cause
inconsistencies in the results obtained in the different stu-
dies. Recent studies have demonstrated that the expansion
of lymphatic networks within the lymph nodes occurred
prior to the onset of metastasis [3]. Therefore, it appears
likely that the status of lymph node metastasis cannot be
used as an early predictor of lymphatic invasion. These
findings, as well as the absence of a correlation between
ECM1 and VEGF-C expression in the tumor cells and
lymph node metastasis may be explained by the fact that
metastatic establishment in lymph nodes is a complex
process in which multiple growth factors are involved.
Lymphangiogenesis initiated by lymphangiogenic factors
secreted from tumor cells occurs at the onset of metasta-
sis. Hence, our finding that ECM1 and VEGF-C expres-
sion is not associated with lymph node metastasis is
plausible. One possible explanation is that ECM1 or
VEGF-C might be responsible for the early events relating
to lymphatic spread prior to lymph node metastasis [30].
To explore whether ECM1 expression was associated
with the metastatic character of the breast cancer cells, we
analyzed the ECM1 expression profiles between the pri-
mary tumors and the metastatic foci in individuals with
metastasis. Theoretically, the metastatic focus in the nodes
and the primary nests are consanguine. Additionally, we
found two cases that were ECM1-negative in the primary
tumor, but ECM1-positive in the corresponding lymph
node metastases. Han et al. [29] and Wang et al. [10] also
found a case that was ECM1-negative in the primary
tumor but exhibited ECM1-positive staining in its corre-
sponding metastatic focus. This suggests that ECM1 is
associated with breast cancer cells that have a potential for
metastasis, although the exact mechanism remains
unclear. Recently, it has been reported that ECM1 is selec-
tively expressed in Type 2 helper T cells (TH2l y m p h o -
cytes), and regulates TH2 cell migration via expression of
KLF2 and S1P1 [33]. Whether ECM1 regulates metastasis
associated genes, or interacts with other extracellular
matrix proteins, or both, or is involved in tumor cells
migration is currently unknown.
Recently published work suggests that overexpression of
TFAP2a or TFAP2g induced ECM1 expression in human
mammary epithelial cells could result in modified ER
Table 8 Correlation between ECM1 staining and LMVD
(LMV per 200× field of vision)
ECM1 staining
Tissue type - + U P
Cancer tissues 7.50 ± 1.63(10) 15.17 ± 2.14(31) 85.50 0.045*
Lymph nodes 2.71 ± 0.62(28) 11.46 ± 2.77(13) 48.00 0.000***
“+”, “++” and “+++” for ECM1 immunochemistry staining was all grouped
together as “+”.
* P < 0.05 and *** P < 0.001 is considered statistically significant
Within parenthesis: number of eligible cases. Abbreviation: LMVD: lymphatic
microvessel density; LMV per 200× field of vision: lymphatic microvessel 200×
field of vision
Table 9 Correlation between ECM1 staining intensity and LMVD (LMV per 200× field of vision)
ECM1 expression intensity
Tissue type - + ++ +++ r P
Cancer tissues 7.50 ± 1.63(10) 14.73 ± 2.81(22) 15.57 ± 3.80(7) 1.50 ± 2.50(2) 0.347 0.026*
Lymph nodes 2.71 ± 0.62(28) 10.44 ± 3.06(9) 14.00 ± 9.08(3) 13(1) 0.604 < 0.001*
* P < 0.05 is considered statistically significant
Within parenthesis: number of eligible cases. Abbreviation: LMVD: lymphatic microvessel density; LMV per 200× field of vision: lymphatic microvessel 200× field
of vision
Table 10 Correlation between VEGF-C staining and LMVD
(LMV per 200× field of vision)
VEGF-C staining
Tissue type - + U P
Cancer tissues 8.88 ± 2.57(8) 13.94 ± 2.04(33) 93.50 0.211
Lymph nodes 3.15 ± 1.19(26) 11.88 ± 2.32(25) 75.00 < 0.001***
“+”, “++” and “+++” for VEGF-C immunochemistry staining was all grouped
together as “+”
*** P < 0.05 is considered statistically significant
Within parenthesis: number of eligible cases. Abbreviation: LMVD: lymphatic
microvessel density; LMV per 200× field of vision: lymphatic microvessel 200×
field of vision
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Page 10 of 12responsiveness [34]. In our study, ER positive tumors
appeared more likely to be ECM1-positive. This finding
i n d i c a t e st h a tE C M 1i sa s s o c i a t e dw i t he s t r o g e nr e s p o n -
siveness in breast cancer. Further investigations are needed
t op r o v et h i sa sw e l la st h er o l eo fE C M 1i nt h eb r e a s t
estrogen-receptor-axle. It will be interesting to see whether
ECM1 could become a new target for breast cancer
hormonotherapy.
It is possible that ECM1 alone is not sufficient to facil-
itate lymphangiogenesis, which may require multiple
lymphangiogenic factors. VEGF-C is the most exten-
sively studied molecule for tumor lymphangiogenesis
and we found that VEGF-C has potential synergy with
ECM1 for facilitating lymphatic metastasis. One limita-
tion of this study was the relatively small sample size.
Nevertheless, our findings support a potential role for
ECM1 in the lymphatic progression of breast cancer, an
area that will require further study to explore the
mechanisms involved.
Conclusions
Our data demonstrate that both ECM1 and VEGF-C
mRNA and protein were overexpressed in breast cancer
specimens compared to their corresponding normal
counterparts and axillary lymph nodes. ECM1 protein
expression was positively correlated with estrogen
r e s p o n s i v e n e s sa n dL M V D ,b u tw a sn o tc o r r e l a t e dw i t h
the status of the lymph node metastasis in this study.
ECM1 and VEGF-C may have a synergistic effect on
lymphangiogenesis to facilitate the lymphatic metastasis
of breast cancer.
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